HIGHLIGHTS
- who: Lixian Zhong et al. from the University of California San Francisco, San Francisco, California, United States of America, VA Northern California, Martinez, California, United States of America have published the research: Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost- Effectiveness Analysis, in the Journal: PLOS ONE | www.plosone.org of May/22,/2013
- what: The aim of this study is to evaluate the cost-effectiveness of the two new treatment options versus two placebos for patients with mCRPC following docetaxel treatment failure over 18 months from a the authors societal . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.